Cellphire Inc., based in Rockville, is developing cell stabilization technologies that also have application in the delivery of therapeutics and labeled reagents in the diagnosis of traumatic brain injuries. The company collaborates with Bogdan Stoica, assistant professor, department of anesthesiology, University of Maryland, Baltimore, to refine and test the efficacy of the company's technology for treating brain trauma. ($135,165)
http://www.mtech.umd.edu/news/news_story.php?id=8932
About Cellphire
Cellphire, Inc. is a biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to all cell types, including platelets, to develop lifesaving products. Its lead product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine. For more information, visit www.cellphire.com.
Contacts:
Media
Sharon Burns
Director, Communications
sburns@cellphire.com
Investor Relations
Tom Dann
Chief Investment Officer
tdann@cellphire.com